Merck & Co Inc
(LTS:0QAH)
$
131.3
0 (0%)
Market Cap: 260.35 Bil
Enterprise Value: 283.89 Bil
PE Ratio: 21.58
PB Ratio: 5.86
GF Score: 81/100 
Merck & Co Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 18, 2020 / 03:40PM GMT
Release Date Price:
$76.97
(+0.63%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello. Welcome to the UBS Global Healthcare Conference. This is day 1. Our next presentation or fireside chat is with Merck & Co. I'm very happy to have with me today, EVP and Chief Marketing Officer, Mike Nally; as well as Head of Investor Relations, Peter Dannenbaum. Mike, Peter, thank you so much for joining us today.
Michael T. Nally
Merck & Co., Inc. - CMO & Executive VP
Thanks, Navin. We appreciate the opportunity.
Peter Dannenbaum
Merck & Co., Inc. - VP of IR
Thanks, Navin.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Great. So we -- we're just going to jump into questions here. We can't escape COVID, obviously, and so maybe I'll just start off with a couple of high-level questions
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers